Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma
- 1 August 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (8) , 1163-1164
Abstract
This Viewpoint advocates for increased use of neoadjuvant therapy in the treatment of localized pancreatic adenocarcinoma.Keywords
This publication has 6 references indexed in Scilit:
- Faculty Opinions recommendation of FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.2020
- Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2019
- Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapySurgery, 2019
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerNew England Journal of Medicine, 2018
- Value of lymph node positivity in treatment planning for early stage pancreatic cancerSurgery, 2017
- Hospital Volume, Complications, and Cost of Cancer Surgery in the ElderlyJournal of Clinical Oncology, 2015